AB-1002
- Generic Name
- AB-1002
AskBio's AB-1002 Gene Therapy Shows Promise in Heart Failure
• AskBio's AB-1002 gene therapy demonstrates preliminary efficacy in treating congestive heart failure, with no serious adverse events reported in early clinical data.
• The Phase 1 study (NAN-CS101) showed clinically meaningful improvements in left ventricular ejection fraction (LVEF) in a subset of patients with NYHA Class III heart failure.
• AB-1002 delivers a gene coding for inhibitor-1 (I-1), which blocks protein phosphatase 1 (PP1), a target implicated in the development of heart failure.
• Bayer's AskBio is planning a Phase 2 trial to further evaluate the safety and efficacy of AB-1002 in a larger patient population.
AskBio's AB-1005 Gene Therapy for Parkinson's Disease Gains FDA RMAT Designation and Enrolls First Phase II Participants
• AskBio's AB-1005, a gene therapy for Parkinson's disease, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, potentially expediting its development.
• The RMAT designation was supported by positive 36-month Phase Ib data, demonstrating a favorable safety profile and encouraging trends in clinical outcome measures.
• The Phase II REGENERATE-PD trial, evaluating AB-1005 in moderate-stage Parkinson's, has randomized its first participants across sites in the US, with plans to expand to Europe.
• AB-1005 delivers glial cell line-derived neurotrophic factor (GDNF) to promote the survival of dopaminergic neurons, addressing a critical unmet need in Parkinson's treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath